222 related articles for article (PubMed ID: 21928373)
1. Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery.
Kasparek MS; Bruckmeier A; Beigel F; Müller MH; Brand S; Mansmann U; Jauch KW; Ochsenkühn T; Kreis ME
Inflamm Bowel Dis; 2012 Jul; 18(7):1207-13. PubMed ID: 21928373
[TBL] [Abstract][Full Text] [Related]
2. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
[TBL] [Abstract][Full Text] [Related]
3. The risks of post-operative complications following pre-operative infliximab therapy for Crohn's disease in patients undergoing abdominal surgery: a systematic review and meta-analysis.
Rosenfeld G; Qian H; Bressler B
J Crohns Colitis; 2013 Dec; 7(11):868-77. PubMed ID: 23466411
[TBL] [Abstract][Full Text] [Related]
4. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
[TBL] [Abstract][Full Text] [Related]
5. Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease.
Kotze PG; Saab MP; Saab B; da Silva Kotze LM; Olandoski M; Pinheiro LV; Martinez CA; Ayrizono ML; Magro DO; Coy CS
Dig Dis Sci; 2017 Feb; 62(2):456-464. PubMed ID: 27933472
[TBL] [Abstract][Full Text] [Related]
6. Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy.
Cullen G; Vaughn B; Ahmed A; Peppercorn MA; Smith MP; Moss AC; Cheifetz AS
Inflamm Bowel Dis; 2012 Apr; 18(4):691-6. PubMed ID: 21648022
[TBL] [Abstract][Full Text] [Related]
7. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.
Colombel JF; Loftus EV; Tremaine WJ; Pemberton JH; Wolff BG; Young-Fadok T; Harmsen WS; Schleck CD; Sandborn WJ
Am J Gastroenterol; 2004 May; 99(5):878-83. PubMed ID: 15128354
[TBL] [Abstract][Full Text] [Related]
8. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.
Kunitake H; Hodin R; Shellito PC; Sands BE; Korzenik J; Bordeianou L
J Gastrointest Surg; 2008 Oct; 12(10):1730-6; discussion 1736-7. PubMed ID: 18709514
[TBL] [Abstract][Full Text] [Related]
9. Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis.
Yang ZP; Hong L; Wu Q; Wu KC; Fan DM
Int J Surg; 2014; 12(3):224-30. PubMed ID: 24394691
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis.
Kopylov U; Ben-Horin S; Zmora O; Eliakim R; Katz LH
Inflamm Bowel Dis; 2012 Dec; 18(12):2404-13. PubMed ID: 22467533
[TBL] [Abstract][Full Text] [Related]
11. Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease.
Nasir BS; Dozois EJ; Cima RR; Pemberton JH; Wolff BG; Sandborn WJ; Loftus EV; Larson DW
J Gastrointest Surg; 2010 Dec; 14(12):1859-65; discussion 1865-6. PubMed ID: 20872084
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with Crohn's disease--a nationwide cohort study.
Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
Aliment Pharmacol Ther; 2013 Jan; 37(2):214-24. PubMed ID: 23190161
[TBL] [Abstract][Full Text] [Related]
14. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
15. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS;
Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
[TBL] [Abstract][Full Text] [Related]
16. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-alpha treatments and obstructive symptoms in Crohn's disease: a prospective study.
Condino G; Calabrese E; Zorzi F; Onali S; Lolli E; De Biasio F; Ascolani M; Pallone F; Biancone L
Dig Liver Dis; 2013 Mar; 45(3):258-62. PubMed ID: 23195667
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients.
Syed A; Cross RK; Flasar MH
Am J Gastroenterol; 2013 Apr; 108(4):583-93. PubMed ID: 23481144
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease.
Aggarwal D; Limdi JK
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):13-9. PubMed ID: 25341058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
